Please assess the completion status of the following clinical trial:

Trial Title: Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is aged 6 months to 21 years inclusive.~* Subject is diagnosed with neuroblastoma, hepatoblastoma, osteosarcoma or extracranial germ cell tumors and has not been previously treated with cisplatin or carboplatin.~* Subject is scheduled to receive a chemotherapy regimen that includes a cumulative cisplatin dose of ≥ 200 mg/m2.~* Subject has normal baseline auditory function, defined as ≤ 20 dB from 2000 to 8000 Hz, in both ears and does not have a history of sensorineural hearing loss.~Exclusion Criteria:~* Subject has middle ear effusion upon clinical examination.~* Subject has a history of central nervous system radiotherapy that encompasses all or part of the cochlea or will receive such radiation therapy during the course of the study.~* Subject is receiving sodium-thiosulfate or amifostine therapy with chemotherapy.~* Subject is currently participating on a separate otoprotection clinical study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- OTO-104 (Type: ACTIVE_COMPARATOR): One of the subject's ears will receive up to three administrations of study drug prior to cisplatin-based therapy
- Control (Type: NO_INTERVENTION): The ear not receiving OTO-104 will receive no treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).